LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Strona główna・Stock List・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Closed

SectorHealthcare

15.62 2.29

Buy Sell

Overview

Share price change

24h

Current

Min

14.91

Max

15.63

Key metrics
By Trading Economics
Income	10M 32M
Sales	3.5M 73M
P/E Sector Avg	28.875 80.03
EPS	0.23
Profit margin	42.945
Employees	130
EBITDA	8.7M 37M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+7.77% upside

Market Stats
By TradingEconomics
Market Cap	398M 2.1B
Previous open	13.33
Previous close	15.62

News Sentiment

By Acuity

34%

66%

109 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

8.1 / 8.21 Support & Resistance

Aurinia Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lis 2025, 09:49 UTC

Hot Stocks

Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir -- WSJ

Peer Comparison

Price change

Aurinia Pharmaceuticals Inc Forecast

Price Target

By TipRanks

7.77% upside

12 Months Forecast

Average 16.5 USD 7.77%

High 21 USD

Low 13 USD

Based on 6 Wall Street analysts offering 12 month price targets forAurinia Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Aurinia Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

8.1 / 8.21Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

109 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.